P-glycoprotein limits the brain penetration of olopatadine hydrochloride, H1-receptor antagonist

Drug Metabolism and Pharmacokinetics

Volumn 23, Issue 2, 2008, Pages 106-114

  Mimura, Nobuhito ^a   Nagata, Yoshinori ^a   Kuwabara, Takashi ^a   Kubo, Nobuo ^b   Fuse, Eiichi ^a  

^a KYOWA HAKKO KOGYO CO LTD   (Japan)

^b KANSAI MEDICAL UNIVERSITY   (Japan)

Author keywords

Brain distribution; Mouse; Olopatadine; P glycoprotein; Pharmacokinetics; Second generation H1 antagonists

Indexed keywords

CYCLOSPORIN A; GLYCOPROTEIN P; OLOPATADINE; DIBENZOXEPIN DERIVATIVE; HISTAMINE H1 RECEPTOR ANTAGONIST;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG PENETRATION; DRUG UPTAKE; ENZYME SUBSTRATE; GENETIC TRANSFECTION; KNOCKOUT MOUSE; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; PROTEIN FUNCTION; STRAIN DIFFERENCE; TIME TO MAXIMUM PLASMA CONCENTRATION; WILD TYPE; ANIMAL; BLOOD BRAIN BARRIER; BRAIN; CELL STRAIN; METABOLISM; MOUSE MUTANT; PHYSIOLOGY;

ANIMALS; AREA UNDER CURVE; BLOOD-BRAIN BARRIER; BRAIN; DIBENZOXEPINS; HISTAMINE H1 ANTAGONISTS; LLC-PK1 CELLS; MALE; MICE; MICE, KNOCKOUT; P-GLYCOPROTEIN;

EID: 43749118939     PISSN: 13474367     EISSN: 18800920     Source Type: Journal    
DOI: 10.2133/dmpk.23.106     Document Type: Article

References (27)

1. Hindmarch, I. and Shamsi, Z.: Antihistamines: models to assess sedative properties, assessment of sedation, safety and other side-effects. Clin Exp Allergy. 29: 133-142 (1999).
2. Mattila, M. J. and Paakkari, I.: Variations among non-sedating antihistamines: are there real differences? Eur J Clin Pharmacol. 55: 85-93 (1999).
3. 1 antagonists measured by positron emission tomography. Br J Pharmacol. 116: 1649-1655 (1995).
4. 11C-doxepin positron emission tomography. J Clin Pharmacol. 44: 890-900 (2004).
5. 11C-doxepin in placebo-controlled crossover study design in healthy subjects: a comparison of olopatadine and ketotifen. Br J Clin Pharmacol. 61: 16-26 (2005).
6. Lin, J. H.: How significant is the role of P-glycoprotein in drug absorption and brain uptake? Drugs Today. 40: 5-22 (2004).
7. Tsuji, A.: Transporter-mediated drug interactions. Drug Metabol Pharmacokin. 17: 253-274 (2002).
8. Thiebaut, F., Tsuruo, T., Hamada, H., Gottesman, M. M., Pastan, I. and Willingham, M. C.: Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA. 84: 7735-7738 (1987).
9. Croop, J. M., Raymond, M., Haber, D., Devault, A., Arceci, R. J., Gros, P. and Housman, D. E.: The three mouse multidrug resistance (mdr) genes are expressed in a tissue-specific manner in normal mouse tissues. Mol Cell Biol. 9: 1346-1350 (1989).
10. Hsu, SI-H., Lothstein, L. and Horwitz, S. B.: Differential overexpression of three mdr gene family members in multidrug resistant J774.2 mouse cells. Evidence that distinct Pglycoprotein precursors are encoded by unique mdr genes. J Biol Chem. 264: 12053-12062 (1989).
11. 1-antagonists. Drug Metab Dispos. 31: 312-318 (2003).
12. Chishty, M., Reichel, A., Siva, J., Abbot, N. J. and Begley, D. J.: Affinity for the P-glycoprotein efflux pump at the blood-brain barrier may explain the lack of CNS side-effects of modern antihistamines. J Drug Target. 9: 223-228 (2001).
13. Cvetkovic, M., Leake, B., Fromm, M. F., Wilkinson, G. R. and Kim, R. B.: OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab Dispos. 27: 866-871 (1999).
14. 1-antagonist epinastine across the blood-brain barrier. Drug Metab Dispos. 32: 519-524 (2004).
15. Ohashi, R., Kamikozawa, Y., Sugiura, M., Fukuda, H., Yabuuchi, H. and Tamai, I.: Effect of P-glycoprotein on intestinal absorption and brain penetration of antiallergic agents bepotastine besilate. Drug Metab Disos. 34: 793-799 (2006).
16. Polli, J. W., Baughman, T. M., Humphreys, J. E., Jordan, K. H., Mote, A. L., Salisbury, J. A., Tippin, T. K. and Serabjit-Singh, C. J.: P-glycoprotein influences the brain concentrations of cetirizine (Zyrtec®), a second-generation non-sedating antihistamine. J Pharm Sci. 92: 2082-2089 (2003).
17. Tahara, H., Kusuhara, H., Fuse, E. and Sugiyama, Y.: Pglycoprotein plays a major role in the efflux of fexofenadine in the small intestine and blood-brain barrier, but only a limited role in its billiary excretion. Drug Metab Dispos. 33: 963-968 (2005).
18. 1-antagonist ebastine and its metabolite carebastine. J Drug Target. 8: 383-393 (2000).
19. Ohmori, K., Hasegawa, K., Tamura, T., Miyake, K., Matsubara, M., Masaki, S., Karasawa, A., Urayama, N., Horikoshi, K., Kajita, J., Hasegawa, M., Taniguchi, K., Komada, T. and Kawamoto. Y.: Properties of olopatadine hydrochloride, a new antiallergic/antihistaminic drug. Arzneim-Forsch/ Drug Res. 54: 809-829 (2004).
20. Tanigawara, Y., Okamura, N., Hirai, M., Yasuhara, M., Ueda, K., Kioka, N., Komano, T. and Hori, R. Transport of digoxin by human P-glycoprotein expressed in a porcine kidney epithelial cell line (LLC-PK1). J Pharm Exp Ther. 263: 840-845 (1992).
21. Ueada, K., Okamura, N., Hirai, M., Tanigawara, Y., Saeki, T., Kioka, N., Komano, T. and Hori, R.: Human P-glycoprotein transports cortisol, aldosterone and dexamethasone, but not progesterone. J Biol Chem. 267: 24248-24252 (1992).
22. Adachi, Y., Suzuki, H. and Sugiyama, Y.: Comparative studies on in vitro methods for evaluating in vivo function of MDR1 PGlycoprotein. Pharm Res. 18: 1660-1668 (2001).
23. Mizuno, N. and Sugiyama, Y.: Drug transporters: Their role and importance in the selection and development of new drugs. Drug Metabol Pharmacokin. 17: 93-108 (2002).
24. Common Technical Document for the Registration of Pharmaceuticals for Human Use http://211.132.8.246/shinyaku/g0012/08/ 23012400_21200AMZ00645.html (accessed 02/07/07)
25. Jung, S. J., Choi, S. O., Um, S. Y., Kim, J. L., Choo, H. Y. P., Choi, S. Y. and Chung, S. Y.: Prediction of the permeability of drugs through study on quantitative structure-permeability relationship. J Pharm Biomed Anal. 41: 469-475 (2006).
26. Kuwabara, T., Ohishi, T., Ikenaga, T., Nishiie, H., Satoh, T., Kobayashi, H. and Kobayashi, S.: Disposition of KW-4679 (6): pharmacokinetics in experimental animals. Xenobio Metabol Dispos. 10: 707-721 (1995).
27. Holgate, S. T., Canonica, F. E. R., Simons, M., Taglialatela, M., Tharp, H., Timmerman, H. and Yanai, K.: Consensus group on new-generation antihistamines (CONGA): present status and recommendations. Clin Exp Allergy. 33: 1305-1324 (2003).